@article{Rayman_G-2020_6638,
title = {Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic},
author = {Rayman, G. and Lumb, A. and Kennon, B. and Cottrell, C. and Nagi, D. and Page, E. and Voigt, D. and Courtney, H. and Atkins, H. and Platts, J. and Higgins, K. and Dhatariya, K. and Patel, M. and Narendran, P. and Kar, P. and Newland-Jones, P. and Stewart, R. and Burr, O. and Thomas, S.},
month = {jun},
year = {2020},
abstract = {During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.},
pages = {1214-1216},
volume = {37},
issue = {7},
journal = {Diabetic Medicine},
publisher = {Wiley},
url = {https://doi.org/10.1111/dme.14328},
}
